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 Abstract 
Background 
 Lapatinib, a dual EGFR and HER2 inhibitor has shown disappointing results in clinical 
trials of metastatic Oesophago-Gastric Adenocarcinomas (OGA), and in vitro studies 
suggest that MET, IGFR, and HER3 confer resistance. This trial applied Lapatinib in 
the curative neo-adjuvant setting and investigated the feasibility and utility of 
additional endoscopy and biopsy for assessment of resistance mechanisms ex vivo 
and in vivo. 
 
Methods 
Patients with HER2 over-expressing OGA were treated for 10 days with Lapatinib 
monotherapy, and then in combination with 3 cycles of Oxaliplatin and Capecitabine 
prior to surgery. Endoscopic samples were taken for molecular analysis at: baseline 
including for ex vivo culture +/- Lapatinib to predict in vivo response, post Lapatinib 
monotherapy and at surgery. Immunohistochemistry (IHC) and proteomic analysis 
was performed to assess cell kinetics and signalling activity. 
 
Results  
The trial closed early (n=10) due to an anastomotic leak in 2 patients for which a 
causative effect of Lapatinib could not be excluded. The reduction in 
Phosphorylated-HER2 (P-HER2) and P-EGFR in the ex vivo treated biopsy 
demonstrated good correlation with the in vivo response at day 10. Proteomic 
analysis pre and post-Lapatinib demonstrated target inhibition (P-ERBB2, P-EGFR, P-2  
PI3K, P-AKT, P-ERK) which persisted until surgery.  There was also significant 
correlation between the activation of MET with the level of P-Erk (P=0.0005) and P-
PI3K:T-PI3K (Total PI3K) ratio (p=0.0037). There was no significant correlation 
between the activation status of IGFR and HER3 with downstream signalling 
molecules.  
 
Conclusion  
Additional endoscopy and biopsy sampling for multiple biomarker endpoints was 
feasible and confirmed in vitro data that MET is likely to be a significant mechanism 
of Lapatinib resistance in vivo. 
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Introduction 
The incidence of Oesophago-Gastric Adenocarcinoma (OGA), has been increasing 
rapidly (CancerResearchUK, 2015), but 5 yr overall survival remains poor, and it is 
the 6th most common cause of cancer related death.  Locally advanced (non-
metastatic) tumours are treated by surgery, and the addition of chemotherapy has 
improved 5yr overall survival from 23% to 36% (Cunningham et al., 2008). 16.6%  of 
OGAs over-express HER2 (Van Cutsem et al., 2014) and data suggests that this up-
regulation occurs early in the process of carcinogenesis at the stage of pre-invasive 
Barrett’s oesophagus and gastric intraepithelial neoplasia (Paterson et al., 2013a, 
Fassan et al., 2012). Trastuzumab, a monoclonal antibody to HER2, has shown 
significant activity in HER2 overexpressing gastric cancer, although the clinical use so 
far has been restricted to the metastatic setting (Bang et al., 2010).  Lapatinib, a dual 
EGFR and HER2 receptor tyrosine kinase inhibitor has also been investigated in 
metastatic disease but response activity does not appear to be as great as for 
Trastuzumab. A Phase II monotherapy study showed a very modest response rate to 
single agent Lapatinib (Iqbal et al., 2011), and when used in combination with 
chemotherapy (paclitaxel) in the TyTan trial, only modest gains in survival were 
observed (11m vs 8.9m p=0.1044) (Satoh et al., 2014). The TRIO-013/LOGiC trial, a 
randomised phase III trial evaluating the combination of Capecitabine/Oxaliplatin 
with or without Lapatinib in the 1st line treatment of metastatic OGAs demonstrated 
a non-significant increase in overall survival in the Lapatinib arm (overall survival of 
12.2m vs 10.5m, p=0.35)(Hecht JR, 2013) whilst the recent Phase 2 trial comparing 
Lapatinib with or without capecitabine in the second line setting demonstrated a 
very modest response rates of 11% in combination with  chemotherapy and no 4  
responders in the Lapatinib monotherapy arm (Lorenzen et al., 2015). These results 
point to significant primary resistance mechanisms,.  
Targetting HER2 in gastric cancer cell lines and xenografts with tyrosine kinase 
inhibitors (TKIs) or monoclonal antibodies results in inhibition of the phosphorylated 
receptor and downstream signalling through proliferative pathways such as PI3K 
(Wainberg et al., 2010, Chen et al., 2012). However, signalling through alternative 
receptor tyrosine kinases such as MET (Hepatocyte Growth Factor Receptor), HER3, 
IGF1R (Insulin-like Growth Facotor Receptor-1) were noted to produce resistance to 
Lapatinib (Zhang et al., 2014). Inhibiting MET or IGFR activation with their 
corresponding TKI restored Lapatinib sensitivity which was associated with a 
decrease in downstream activation of Akt and Erk in vitro. Similar work on cell lines 
demonstrated that the use of TKI combinations based on RTK activation status 
resulted in greater inhibition of proliferation of OGA cell lines (Paterson et al., 
2013b). Though these in vitro studies shed some insight into the mechanisms of 
Lapatinib resistance, they may not represent the situation in vivo. Studies have 
explored the use of patient derived xenografts and organoids for drug sensitivity 
testing (Dobbin et al., 2014, Sachs and Clevers, 2014), but the major disadvantage 
with these methods is the time required to perform these assays, which means that 
that results cannot be delivered in a timely manner to inform patient management. 
Simple and rapid methods need to be developed to provide biomarker evidence to 
help guide clinical decision making. Options include the use of ex vivo treated 
tumour biopsies, or repeat biopsies after window periods of therapy. This is 
particularly feasible for OGA which is accessible endoscopically. The Lapatinib in 
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Early Oesophago-Gastric cancer (LEO) trial assessed Lapatinib as first line therapy in 
the curative setting for OGA and aimed to:  
1.) To assess the safety and toxicity profile of Lapatinib with 
chemotherapy, when used peri-operatively for patients on a radical 
pathway.  
2.) To test whether an ex vivo assay examining the ability of Lapatinib to 
suppress HER2 and EGFR could predict in vivo response to 10 days of 
Lapatinib monotherapy.  
3.) To establish if assays of downstream signalling performed on biopsies 
taken before and after 10 days of Lapatinib monotherapy could 
indicate mechanisms of resistance/sensitivity to the drug 
4.) Correlate the molecular indicators of response to imaging criteria 
(functional 18FDG-PET and CT imaging) along with clinical outcome 
measures such as R0 resection rate, complete pathological response 
and overall survival. 
 
Methods and Materials 
Trial Design 
This was a 2 centre open label trial of neoadjuvant treatment with Lapatinib alone 
and then in combination with Oxaliplatin and Capecitabine in HER2 expressing 
oesophageal or gastric cancers undergoing curative therapy.  
All patients provided written informed consent prior to entry on the trial, and the 
study protocol was approved by a multi-centre research ethics committee, and a 
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Clinical Trial Authorisation (CTA) was granted (number 12854/0235/001-0001) with 
Lapatinib, Capecitabine and Oxaliplatin listed as Investigational Medicinal Products.  
 
Fig 1 Study design where patients undergo a baseline biopsy and ex vivo sample was 
taken at D0. Patients then received 10 days of Lapatinib monotherapy after which a 
repeat biopsy and functional imaging was performed. Patients went on to receive 3 
cycles of Oxaliplatin and Capecitabine concurrent with Lapatinib on a 21 day cycle, 
followed by definitive surgery. 
 
Power Calculation 
This is a molecular biomarker study and thus designed to examine molecular rather 
than clinical endpoints. The primary objective was to compare the molecular 
response in biopsies taken pre-treatment, which were then treated with Lapatinib ex 
vivo with the molecular response in a biopsy taken after 10 days of oral Lapatinib. It 
was anticipated that concordant response outcomes (no change or decrease) would 
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be observed for at least 80% to 85% patients, with a 5% significance (one-sided) level 
and 80% power, 13 patients would need to be recruited.  
 
Patient Selection 
Patients were enrolled with histologically confirmed OGA which over expressed 
HER2, defined as either 3+ staining intensity for HER2 on immunohistochemistry, or 
2+ staining but shown to have HER2 amplification by FISH (Bang et al., 2010). All 
patients were deemed to have surgically resectable disease on presentation based 
on CT, PET CT, Endoscopic Ultrasound (oesophageal cases) and staging laparoscopy 
(gastric cases) and needed to be fit for both chemotherapy and surgery, with 
adequate haematological parameters (WBC ≥3.0×109/L, Plts≥100×109/L, Hb≥9g/dL), 
renal function (measured or calculated Cr Clearance ≥60ml/min) and liver function 
(Bilirubin≤1.5×ULN, ALT/AST≤1.5×ULN. ALP≤2.5×ULN). They needed to be able to 
swallow oral medication and be over 18yrs of age. Patients with abnormal cardiac 
function determined by echocardiography/MUGA scan, or a history of interstitial 
lung disease were excluded. Those who had previously received chemotherapy or 
Lapatinib were excluded as were those with a known G6PD deficiency. Cases of 
known HIV, Hepatitis C or B infection were also excluded.  
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Treatment 
Patients initially received 10 days of treatment with Lapitinib 1250mg once a day. 
This period was used to assess the effect of Lapatinib alone on the tumour. From day 
11, patients went on to receive 3 cycles of Oxaliplatin (130mg/m2) and Capecitabine 
1700mg/m2 whilst continuing Lapatinib. On completion of neoadjuvant therapy, the 
patient went on to have definitive surgery in the form of an oesophagectomy or 
gastrectomy depending on the location of the tumour. 
 
Assessment 
Toxicity was assessed using the National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE) Version 3.0. Survival was determined by either 
confirmed date of death, or censored at the last recorded trial follow up event. The 
Kaplan Meier method was adopted for the survival analysis. 
PET CT scans were performed on day D0 and day D10 after treatment with Lapatinib 
monotherapy. The fall in the absolute maximum Standard Uptake Value (SUV) and 
for a region of interest (ROI) of 1.5cm diameter circle at D0 and D10 was reported by 
an Administration of Radioactive Substances Committee (ARSAC) accredited 
radiologist. A PET response was defined as a reduction of >35% in the SUV (Lordick 
et al., 2007). CT scans were performed on patients on D0 and on D72. Tumour 
response to therapy was evaluated between the two time points using RESCIST 1.1.  
 
Biopsy Analysis 
Biopsies at baseline, D10 and surgery were taken and the specimen was split equally 
into two parts. One, part was fresh frozen and stored in readiness for processing 9  
using the Collaborative Enzyme Enhanced Reactive Immunoassay (CEER) 
(Prometheus Laboratories Inc, San Diego, USA) and the other part of the biopsy was 
formalin fixed for H&E and IHC analyses.  
At baseline, a further tissue sample was treated with Lapatinib ex vivo. This was 
done by placing the biopsy tissue measuring approximately 0.2cm, on to a mesh 
placed in a well which was then filled with Dulbecco’s Modified Eagles’ Medium 
(Gibco, Invitrogen, Paisley, UK) medium and 10uM Lapatinib (GlaxoSmithKline, 
Uxbridge, UK) or with a control DMSO (Fisher Scientific, Loughborough, UK) so as to 
provide an air-liquid interface. This was then incubated at 37oC for one hour, and 
then fixed in 10% neutral buffered formalin pots, to create paraffin blocks ready for 
IHC.   
 
All samples were stained by IHC for P-HER2, HER2, P-EGFR, P-Erk, P-Akt, (Cell 
Signalling), EGFR (Novacastra)  and MET (Santa Cruz Biotechnology) using the Leica 
Bond Max Automated Immunohistochemistry System (Wetzlar, Germany).  Staining 
was scored by 2 independent reviewers using intensity (0=No reactivity or 
membranous staining of tumour cell, 1=Faint/Barely Perceptible membranous 
staining of ≥10% of tumour cells, 2=Weak to moderate complete, basolateral or 
lateral membranous reactivity in ≥10% of tumour cells, 3=Strong complete, 
basolateral or lateral membranous reactivity in ≥10% of tumour cells)(Koopman et 
al., 2015). Scores of 2 and 3 were considered positive whereas 0 and 1 were 
negative, and a response was defined as a positive score becoming negative (Zhang 
et al., 2014). A response was defined as a change from a positive IHC score (2+ or 3+) 
to a negative score (0+ or 1+) for P-HER2 and P-EGFR. Proliferation was assessed by 10  
staining for Ki67 (Leica, Wetzlar Germany), and apoptosis assessed by staining for 
Cleaved Caspase 3 (CC3) (Cell Sginalling) and by using the TUNEL assay (Millipore, 
Consett UK).  A score of 1 to 5 was given based on the percentage of tumour cells 
staining for Ki67 (1=0-20%, 2=21%-40%, 3=41%-60%, 4= 61%-80%, 5=>81%).  Scoring 
CC3 and the TUNEL assay was done my counting all positively staining cancer cells in 
5 high power (40x) fields of view by 2 independent scorers, and the average of all 10 
scores was taken for the purposes of analysis (Li et al., 2008).  
All frozen samples were assayed using the CEER platform (Prometheus Laboratories, 
San Diego, USA) for receptor tyrosine kinase activation (EGFR, HER2, p95, HER3, 
IGFR, MET) and downstream signalling. This could not be done with the ex vivo 
biopsy as it was formalin fixed and further material was not available.   
 
Genomic Analysis 
Whole genome sequencing was available for one patient’s treatment naïve tumour. 
DNA was extracted from fresh frozen tissue samples using the Qiagen DNA Mini Kit 
(Qiagen) as per protocol and sequenced on the Illumina HiSeq platform. Paired DNA 
from blood was sequenced to allow somatic variants to be distinguished from those 
in the germline. BWA was used for alignment against GRCh37 reference from 
Ensembl v71. Variant calling was performed with Somatic Sniper (V1.0.2) and a 
variety of filters was used to exclude low quality calls (Weaver et al., 2014). The 
single nucleotide variation data was assessed using DAVID Bioinformatics resource 
Version 6.7 (National Institute of Allergy and Infectious Diseases (NIAID)). Functional 
annotation was assessed using the Gene Ontology tools and KEGG pathway analysis. 
ASCAT-NGS v.2.1 (Van Loo et al., 2010, Nik-Zainal et al., 2012) was used to infer 11  
tumour copy number data, and a combination of both copy number and single 
nucleotide variation data was analysed in cloneHD to assess clonality (Fischer et al., 
2014).  
 
Statistical Analysis 
For the assessment of the ex vivo assay by IHC, a molecular response was defined as 
a positive P-HER2 or P-EGFR (2+ or 3+) becoming a negative score (0+ or 1+) (Zhang 
et al., 2014). A Kappa correlation coefficient was calculated to assess agreement 
between ex vivo and D10 in vivo response, and between the 2 reviewers for these 
scores. Wilcoxon Rank Sums analysis was performed, between baseline tumour IHC 
characteristics (HER2, EGFR, MET) and predefined clinical outcome (RECIST response, 
complete pathological response, R0 resection).  
HER2, p95HER2 and EGFR activation (phosphorylated to total protein ratio) using 
CEER data was assessed at baseline, D10 and surgery and the Wilcoxon Signed Rank 
Test was used to assess changes between baseline and D10 as well as baseline and 
surgery.  
Correlation between MET, IGFR and HER3 activation (phosphorylated to total protein 
ratio) was correlated with the PI3K, P-Erk, and P-Akt activation (absolute levels of P-
Erk and P-Akt was used as the total protein level was not available for these to 
molecules) using the Spearman Rank Correlation.  
 
Results 
A total of 10 patients were recruited to the trial. The median age of the 10 patients 
was 61.7yrs, with a preponderance for males (70%) which is in keeping with the 12  
epidemiology of the disease. 8 of patients entering the trial had a performance 
status of 0, and the remaining 2 a performance status of 1. The primary site of 
disease was the gastro-oesophageal junction in 6 of cases and the majority of these 
tumours were poorly differentiated (Table 1). All patients bar one had a HER2 IHC 
score of 3+ and only one patient had a tumour with an IHC score of 2, which was 
subsequently confirmed to be amplified by FISH.  
 
 n=10 
Age (yrs) 
Mean  61.7 
Standard Deviation 9.4 
Range 49.7 -75.2 
Sex Male 7 
Female 3 
ECOG Performance Status 0 8 
1 2 
Site of Primary 
Oesophagus 3 
Stomach 1 
GOJ Type 1 1 
GOJ Type II 3 
GOJ Type III 2 
HER2 Staining 3+ 9 
2+ with FISH amplification 2 
Tumour Differentiation Moderate 4 
Poor 6 
T Stage T2 1 
T3 7 
N Stage 
N0 7 
N1 2 
N2 1 
M Stage  M0 0 
 
Table 1 Demographic data on patient cohort, with primary site, HER2 scoring, 
tumour differentiation and stage. 
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The 10 day Lapatinib monotherapy window phase was well tolerated with 100% of 
patients receiving the intended Lapatinib dose with no ≥grade 3 toxicity. With 
regards to the neoadjuvant period of chemotherapy with concurrent Lapatinib, 80% 
of patients received all 3 cycles of chemotherapy.  These toxicities are summarised in 
Table 2.  
n=10 
Lapatinib Monotherapy  
Lapatinib monotherapy toxicities  0 
Lapatinib and Chemotherapy 
Anastomotic leak 2 
Fainting 1 
Mucositis 1 
Candida infection 1 
Nausea 2 
Atelectasis 1 
Dyspepsia 1 
Diarrhoea 2 
Gastrointestinal Pain 1 
Small Bowel Obstruction 1 
Weight Loss 1 
Chest Infection 1 
Hypoxia 1 
Neutropenia 1 
 
Table 2 Adverse events of ≥ Grade 3 experienced by patients during their 
monotherapy window, and concurrent chemotherapy treatment.  
 
The most common adverse effects noted were nausea and diarrhoea. These are in 
keeping with the known individual toxicities of the drugs, especially Capecitabine 
and Lapatinib. 3 patients experienced grade 4 toxicity. This included 2 patients who 
experienced anastomotic leaks. One of these patients died after developing a chest 
infection. This leak rate of 20% was higher than expected given that both tertiary 
centres had leak rates in keeping with the national oesophago-gastric audit of 5%, 14  
and as a result the independent data monitoring committee agreed to suspend 
recruitment to the study after 10 patients had been enrolled (Chadwick G, 2013). 
Median overall survival was 32.4months, and median progression free survival was 
16.4 months. There were no responses by PET at D10 in the maximal SUV of for the 
maximal region of interest (ROI 1.5cm2 circle). 50% of patients had a partial response 
on CT after neoadjuvant therapy, and the rest had stable disease.  
 
Molecular Analysis 
Immunohistochemistry 
Tumour specimens were stained for HER2, EGFR, P-HER2, P-EGFR, MET, as well as 
downstream targets including P-Erk, P-Akt and examples of staining patterns are 
demonstrated in Fig 2.  
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 Fig 2 Immunohistochemistry for the phosphorylated species for the RTKs P-HER2, P-
EGFR and the downstream molecules P-Erk and P-Akt. Examples of staining 
performed using the Axio Slide Scanner (Oberkochen, Germany) at 40x and images 
at a 35% digital zoom. No 3+ staining was observed for P-Akt. 
 
 
 
Assessment of the ex vivo assay 
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The ex vivo assay was used to determine whether it is possible to predict in vivo 
response after 10 days of Lapatinib monotherapy.  
 
There was good agreement between the 2 independent scorers. 3 samples were 
inadequate specimens and so paired data was available for 9 cases for P-HER2 and 8 
for P-EGFR. The Ex vivo and D10 molecular response correlated 89% of the time for 
P-HER2 and 100% for P-EGFR which meets the pre-defined aim of 75%.  
 
Comparison of molecular and clinical outcomes 
As an alternative to the ex vivo culture assay, the IHC results on biopsies sampled 
over time were correlated to clinical outcome measures to assess if any of these 
assays could be a potential biomarker for response to Lapatinib therapy.  
The baseline score for HER2, EGFR and MET (potential resistance mechanism) was 
related to clinical outcome measures. Our hypothesis was that stronger HER2 and 
EGFR staining tumours would be more responsive to Lapatinib, whereas tumours 
with strong MET expression would be resistant to therapy. Wilcoxon-Rank Sum 
Analysis failed to show any association between baseline HER2 scores and the 
clinical outcomes by RECIST response, R0 resection rate, or complete pathological 
response (p=1.000, p=0.660, p=0.606 respectively). Nor was there any associations 
with baseline EGFR score (p= 0.535, p=0.087, p=0.702) or MET scores (p=0.399, 
p=0.615, 0.615 respectively). On target response did not correlate with progression 
free survival or overall survival based on an IHC response (HER2 based response OS 
p= 0.2278 PFS p=0.6650; EGFR based response OS p=0.3938, PFS p=0.3173) or CEER 
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response (HER2 based response OS p=0.4126, PFS p=0.2216; EGFR based response 
OS p=0.2922, PFS p=0.1486). 
P-HER2 Ex vivo 
No Change Response 
In vivo 
No Change 6 0 
Response 1 2 
    Kappa Score for P-HER2 
  Between scorers (weighted) 0.5902 
 Between ex vivo and D10 IHC score 0.7273 
 
    Correlation between ex vivo and D10 in vivo 
 
 
88.9% 
  
    
    
P-EGFR Ex vivo 
No Change Response 
In vivo 
No Change 7 0 
Response 0 1 
    
    Kappa Score for P-EGFR 
  Between scorers 0.832 
 Between ex vivo and D10 IHC score 1 
 
    Correlation between ex vivo and D10 in vivo 
 
 
100.0% 
   
Table 3 Comparison of the ex vivo response to Lapatinib for P-HER2 and P-EGFR, with 
that seen after 10 days of in vivo Lapatinib monotherapy. 
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CEER proteomic analysis 
The target effect of Lapatinib was examined at baseline, D10 and surgery using the 
CEER assay (Fig 3). There was a significant drop in the P-HER2:T-HER2, and P-EGFR:T-
EGFR ratios after only 10 days of Lapatinib monotherapy (p=0.0039 and p=0.0195 
respectively). All 10 patients demonstrated reductions in HER2 activation by day 10 
and 9 of 10 patients had a reduction in EGFR activation. This reduction in growth 
factor signalling persisted to the time of surgery and EGFR signalling remained 
significantly inhibited (p=0.0391), despite a 30 day washout period between 
completing neoadjuvant therapy and surgery. HER2 signalling (PI3K, P-AKT, P-ERK) 
continued to be lower at the time of surgery compared to baseline, although the 
difference did not reach significance (p=0.4961). The truncated form of HER2, 
p95HER2 lacks the extracellular domain, and significant inhibition was again noted at 
D10, which persisted through to surgery (p=0.0078 and p=0.0234 respectively).  
 
  There was a reduction in P-PI3K:T-PI3K activation which mirrors the response in 
HER2 and EGFR, with significant dampening in signalling between baseline and both 
D10 as well as surgery (p=0.03 and p=0.01 respectively). Only phosphorylated assays 
were available for Akt and Erk, and though there was a reduction in median levels, 
this did not reach significance. This maybe because it was not possible to normalise 
the phosphorylated receptor level to the total protein content (assay not available at 
the time) and as such outliers tended to skew the data.   
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 Fig 3 Phosphorylated:Total (P:T)receptor ratios for HER2 (A), EGFR (B) and p95HER2 
(C), along with the downstream molecules P-PI3K:T-PI3K ratio (D), P-Akt (E), and P-
Erk (F) at baseline, D10 and surgery.  
 
The correlation between the activation of RTKs and downstream signalling effectors 
was examined (Fig 4). There was a significant correlation between the activation of 
C-Met with the level of P-Erk (P=0.0005) and P-PI3K:T-PI3K ratio (p=0.0037). There 
was no significant correlation between the activation status of IGFR and HER3 with 
downstream signalling molecules, and no significant correlation was seen between 
the activation status of any receptor and P-Akt. This would suggest that activation of 
C-Met may be a mechanism of Lapatinib resistance in vivo with an R2 value of 0.914 
for P-Erk (Fig 4 Ai) and 0.84 for P-PI3K:T-PI3K (Fig 4 Aii).  
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Fig 4 The ratio of phosphorylated to total protein amount representing the activation 
status of c-met (A), IGFR (B) and HER3 (C), plotted against the activated downstream 
signalling molecules P-Erk (i), and P-PI3K:T-PI3K (ii) ratio. 
 
Whole genome sequencing from a treatment naïve sample was available for one of 
the 4 patients, with persistent MAPK and PI3K pathway activation, which was related 
to MET activation (Fig 4Ai and 4Aii). There were amplifications in EGFR and HER2 
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(total copy number 3 for both with a single copy in the minor allele), but the greatest 
copy number increase was seen with MET with a total copy number of 4. KEGG 
output using single nucleotide variation data revealed significant clustering in the 
Phosphotidylinositol signalling and Wnt pathways, although no mutations were 
observed in the growth proliferative canonical parts of these pathways. 
 
Discussion 
There are 7089 new cases of gastric cancer per year in the UK and 8332 for 
oesophageal cancer in the UK (http://info.cancerresearchuk.org). In the ToGa trial, 
which is the largest assessment of HER2 positivity in this patient group, 16.6% of 
tumours were HER2 positive. This would mean that 2560 patients a year in the UK 
would be HER2 amplified. At present, the ToGa trial has established the use of 
Trastuzumab in the metastatic setting (Bang et al., 2010), but there is no trial 
evidence to support the use of HER2 targeted therapies in patients undergoing 
treatment with curative intent. The use of Lapatinib has been unsuccessful in 
prolonging survival in metastatic patients with HER2 overexpressing OGA (Satoh et 
al., 2014, Iqbal et al., 2011, Hecht JR, 2013, Lorenzen et al., 2015). 
The LEO trial assessed the use of Lapatinib in the peri-operative setting where 
median overall survival was 32.4months. This compares to previous trials where 
surgery alone and in combination with peri-operative chemotherapy demonstrated 
median overall survival rates of 18-24 months (Cunningham et al., 2006, Allum et al., 
2009). Lapatinib monotherapy was well tolerated and the main grade 3 toxicity 
resulted from the combination with chemotherapy. Grade 3 toxicities such as 
nausea/vomiting and mucositis occurred at a similar rate between the LEO patients 22  
and those seen with ECX alone in the MAGIC trial at around 20% and 10% 
respectively (Cunningham et al., 2006). Rates of grade ≥3 diarrhoea was higher 
within the LEO trial which is in keeping with the fact that both Lapatinib and 
Capecitabine can induce diarrhoea individually, and was similar to the rates seen in 
the TRIO-013/LOGiC trial (Hecht JR, 2013). The most significant toxicities were the 2 
anastomotic leaks, which is a much higher rate than observed in the UK national 
audit (Chadwick G, 2013), which was 7.4% for oesophagectomies and 4.4% for 
gastrectomies. Although with such small numbers in the trial it is difficult to draw 
conclusions, a drug effect could not be excluded for this serious complication which 
resulted in death of one patient, especially in view of the persistent inhibition of 
HER2 and EGFR at the time of surgery.  
 
One of the study endpoints was to examine if an ex vivo assay could help predict 
treatment response. This was done using an organ culture, in which a whole biopsy 
is treated with Lapatinib for an hour, and then fixed in formalin for IHC analysis. The 
ex vivo assay accurately predicted in vivo P-HER2 response in 88.9% of cases, and for 
100% of the cases for P-EGFR. This met the predefined study target of concordance 
of 75%.  This approach may warrant further consideration in other clinical trials.  
 
The analysis comparing baseline predictors of sensitivity, namely IHC staining for 
HER2 and EGFR staining intensity, and biomarkers of resistance (C-MET staining) 
failed to show any correlation with clinical outcomes, namely CT response by RECIST 
criteria, R0 resection rates or complete pathological response. This is in keeping with 
the ToGa trial (Bang et al., 2010) where baseline HER2 scoring did not correlate with 23  
sensitivity to anti-HER2 directed therapy. The reasoning for this is thought to be the 
large amount of heterogeneity observed in staining patterns in Upper GI 
adenocarcinomas when compared to other cancers. Indeed, similar heterogeneity in 
staining was observed in this study, highlighting the need to use robust and validated 
scoring systems such as those used in this study (Koopman et al., 2015).   
Further samples at baseline, D10 and surgery were analysed using the CEER assay, 
which has been previously been shown to be much more sensitive for determining 
activation levels compared to IHC (Lee et al., 2013a). The window design of this trial 
also confirms that 10 days of monotherapy can give information of on target effects 
of the drug, as well as assaying potential primary resistance mechanisms. Compared 
to other methods of assaying drug sensitivity, such as establishment of cell lines and 
organoids, repeat endoscopic biopsies after a window period is relatively simple, 
cheap and effective method of getting molecular response data in a timeframe that 
can be clinically relevant for the patient. The effect of Lapatinib was first examined 
on its primary targets, namely HER2 and EGFR. After 10 days of Lapatinib 
monotherapy, there was a significant reduction in the proportion of activated 
receptors for both HER2 and EGFR. This is particularly important as it appears to 
precede any metabolic response as no response was observed by PET imaging over 
this same time period. There was also significant inhibition of p95, the truncated 
form of HER2 which lacks the extracellular domain. In breast cancer, resistance to 
Trastuzumab has been partly attributed to p95 (Duchnowska et al., 2014), as the 
antibody is unable to bind the protein due to the lack of an extracellular domain, but 
there was significant inhibition of p95 noted in this study by Lapatinib at day 10, 
which continued through to surgery. This highlights that repeat biopsy after a 24  
window period of monotherapy can provide the earliest evidence of on target action 
for Lapatinib, and the drug also significantly inhibits p95.  
A 4-6 week wash out period prior to surgery was used to ensure that the patients 
had recovered fully from the neoadjuvant therapy prior to definitive surgery. This 
period has typically been used with cytotoxic chemotherapy as this usually allows for 
complete marrow recovery. Similar pre-operative washout periods have also been 
used with anti-HER2 agents such as Trastuzumab in breast cancer, and have not 
been associated with an increased operative morbidity (Gianni et al., 2010). The 
CEER data demonstrated that despite a washout period of several weeks, there was 
still significant reduction in EGFR signalling at the time of surgery, with a further non-
significant reduction in HER2 signalling. Although the small numbers make it 
impossible to draw any definitive conclusion, it is possible that this persistent 
inhibition of growth factor signalling pathways at surgery may have contributed to 
the anastomotic leak rate. It should therefore be considered whether the washout 
period required for neo-adjuvant therapy using Lapatinib needs to be longer than 
typically used for traditional chemotherapeutics. This is particularly noteworthy 
given that there are current trials open to recruitment using Lapatinib in a similar 
context with a similar wash out period (Cunningham, 2012).   
Not only is there evidence of receptor deactivation in response to drug but a 
decrease in the activation of downstream molecules such as PI3K, P-Erk and P-Akt. 
This supports the on-target action of Lapatinib on these tumours reducing EGFR and 
HER2 mediated signalling by PI3K and with a trend for reduction of the MAPK 
pathway.  
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Preclinical studies have pointed to RTK crosstalk from METas being an important 
mechanism of resistance to Lapatinib and other HER2 directed therapies  (Liu et al., 
2014, Zhang et al., 2014, Paterson et al., 2013b, Shattuck et al., 2008, Chen et al., 
2012, Ha et al., 2014, Lee et al., 2013b). This study provides some of the first in vivo 
evidence that, MET appears to be the most important RTK in activating proliferative 
pathways (PI3K and MAPK) in the presence of Lapatinib inhibition of EGFR and HER2. 
This was demonstrated by the CEER assay where the activation of the MAPK and 
PI3K pathways after 10 days of Lapatinib monotherapy was significantly correlated 
with the activation of MET, but not with IGFR or HER3 (Fig 4). Larger studies would 
need to be undertaken to fully understand whether this molecular crosstalk has 
implications on clinical outcome as this trial was not powered to detect this. Our 
cohort is also not large enough to adequately correct for differences in staging, or to 
perform a multiple regression analysis in order to correlate clinical outcomes and 
molecular findings.   
Whole genome sequencing was available for one of the patients with persistent 
mitogenic signalling in the presence of Lapatinib, which appeared to be due to MET 
activation. The main canonical pathways for PI3K and MAPK were intact in keeping 
with previous genomic studies in OGA have suggested that point mutations do not 
tend to drive proliferation (Weaver et al., 2014, Dulak et al., 2013). Copy number 
data from this same patientdemonstrated HER2 and EGFR amplification (total copy 
number of 3 for each),but interestingly, the most amplified of the RTKs was MET. 
This supports the finding that activation of these mitogenic pathways at D10 is more 
likely to be due to RTK cross talk from MET by amplification.  
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These in vivo findings suggests that MET mediates Lapatinib resistance and is 
particularly noteworthy given recent interest in using MET inhibitors. These trials 
have failed to demonstrate efficacy of single agent MET TKIs ((Shah et al., 2013) and 
MET targeting antibodies (Cunningham et al., 2015), so it is likely that combination 
therapies should be considered with anti-HER2 therapies used in combination with 
anti-MET agents in the context of well designed stratified trials (Ha et al., 2014). 
This study demonstrated that 10 days of monotherapy followed by CEER analysis can 
reveal in vivo evidence of target activity in a simple, rapid and cheap manner, and in 
addition may provide clinically useful information about patients who may be 
resistant, providing the information for clinicians to make management decisions in 
real time, and to select appropriate targeted therapy in a truly personalised manner.  
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